SRR13780259
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.560
- NOTCH_SIGNALING+0.500
- HEDGEHOG_SIGNALING+0.420
- COAGULATION+0.390
- MYOGENESIS+0.370
- PANCREAS_BETA_CELLS+0.360
- APICAL_JUNCTION+0.320
- UV_RESPONSE_DN+0.320
- TGF_BETA_SIGNALING+0.240
Top 10 suppressed
- E2F_TARGETS-0.730
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V2-0.470
- MYC_TARGETS_V1-0.450
- DNA_REPAIR-0.410
- MITOTIC_SPINDLE-0.310
- MTORC1_SIGNALING-0.310
- INTERFERON_ALPHA_RESPONSE-0.210
- PI3K_AKT_MTOR_SIGNALING-0.210
- UNFOLDED_PROTEIN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613790 | — | A | 0.910 |
| 2 | MBCProject_1078_T2_RNA | — | A | 0.890 |
| 3 | TCGA-BH-A0AZ-01A-21R-A12P-07 | — | A | 0.886 |
| 4 | SRR8518203 | — | A | 0.886 |
| 5 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.875 |
| 6 | TCGA-BH-A0BP-01A-11R-A115-07 | — | A | 0.860 |
| 7 | MBCProject_0063_T3B_RNA | — | A | 0.859 |
| 8 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.855 |
| 9 | TCGA-D8-A1JU-01A-11R-A13Q-07 | — | A | 0.852 |
| 10 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |